.png)
Agenzia Italiana del Farmaco
home
Highlights
-
09 Jul 2025
Press releases
AIFA Board of Directors approves the reimbursability of 7 medicines
A new medicine for moderate to severe ulcerative colitis and new medicine indications for multiple sclerosis and cystic fibrosis are some of the treatments that will be reimbursed by the National Health Service (SSN).
-
30 Jun 2025
Press releases
AIFA Board of Directors approves the reclassification of gliflozines in class A of reimbursed products that can be purchased in pharmacies
Green light also for the repeal of the Therapeutic Plans for the same class of medicines, used against diabetes, severe heart failure and chronic renal failure.
-
23 Jun 2025
Information and communication
The Vaccine Report is online
ADR following vaccination that were registered in 2023 by the National Pharmacovigilance Network (RNF).
-
10 Jul 2025
Press releases
AIFA ospita delegazione del Ministero della Salute greco per condividere esperienze e best practice sull’HTA
Presenti anche i rappresentanti della Commissione Europea e dell’OMS Europa.
News
09 Jul 2025
Monitoring pharmaceutical expenditure
Biosimilar medicines in Italy: AIFA reports updated
08 Jul 2025
Inspections and authorisations
Annual list of manufacturing sites authorized/registered for production/importation of active substances updated to June 30, 2025
04 Jul 2025
Lists of Class A and Class H medicinal products
List of class A and H medicinal products at 15 January 2025
02 Jul 2025
Negotiation and reimbursement
Hepatitis C: update of 30 June 2025 concerning enrolled patients
02 Jul 2025
Companies Section
Payment methods of the 2025 annual fee for Marketing Authorisations (MAs) valid as of 31 December 2024
02 Jul 2025
Access to medicinal products
Direct communication with healthcare professionals on MINIRIN
FarmaciLine
Questions regarding drug efficacy, safety and availability
TOLL-FREE NUMBER
Services
Interactive OsMed - The use of medicines in Italy
An interactive consultation of data on the use of medicines in Italy in the general and regional population, described in terms of expenditure, volumes, typology
